Another GLP-1/GIP/glucagon receptor triagonist, efocipegtrutide (HM15211), is undergoing preclinical studies for its efficacy in the treatment of T2DM, MASH, and Parkinson’s disease [167]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.